Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
| Status: | Terminated |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2010 |
| End Date: | July 2011 |
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for
maintaining uveitis suppression when reducing systemic immunosuppression
maintaining uveitis suppression when reducing systemic immunosuppression
Inclusion Criteria:
- Patients who have completed the entire treatment period of the 24 week core study
Exclusion Criteria:
- Inability or unwillingness to undergo repeated subcutaneous injections; inability to
comply with study or follow-up procedures; any medical or psychiatric condition
which, in the investigator's opinion wouldpreclude the participant from adhering to
the protocol or completing the study per protocol.
Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials